126 related articles for article (PubMed ID: 1323882)
1. Acute effects of sigma ligands on the electrophysiological activity of rat nigrostriatal and mesoaccumbal dopaminergic neurons.
Zhang J; Chiodo LA; Wettstein JG; Junien JL; Freeman AS
Synapse; 1992 Aug; 11(4):267-78. PubMed ID: 1323882
[TBL] [Abstract][Full Text] [Related]
2. Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems.
Gronier B; Debonnel G
Eur J Pharmacol; 1999 Mar; 368(2-3):183-96. PubMed ID: 10193654
[TBL] [Abstract][Full Text] [Related]
3. Further characterization of the effects of BMY 14802 on dopamine neuronal activity.
Zhang J; Chiodo LA; Freeman AS
Synapse; 1993 Dec; 15(4):276-84. PubMed ID: 7908761
[TBL] [Abstract][Full Text] [Related]
4. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
5. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
6. D1 receptor stimulation inhibits dopamine cell activity after reserpine treatment but not after chronic SCH 23390: an effect blocked by N-methyl-D-aspartate antagonists.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1992 Jan; 260(1):409-16. PubMed ID: 1530977
[TBL] [Abstract][Full Text] [Related]
7. Influence of excitatory amino acid receptor subtypes on the electrophysiological activity of dopaminergic and nondopaminergic neurons in rat substantia nigra.
Zhang J; Chiodo LA; Freeman AS
J Pharmacol Exp Ther; 1994 Apr; 269(1):313-21. PubMed ID: 7513359
[TBL] [Abstract][Full Text] [Related]
8. Microiontophoretic studies of the effects of D-1 and D-2 receptor agonists on type I caudate nucleus neurons: lack of synergistic interaction.
Shen RY; Asdourian D; Chiodo LA
Synapse; 1992 Aug; 11(4):319-29. PubMed ID: 1354398
[TBL] [Abstract][Full Text] [Related]
9. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study.
Di Giovanni G; Di Matteo V; Di Mascio M; Esposito E
Synapse; 2000 Jan; 35(1):53-61. PubMed ID: 10579808
[TBL] [Abstract][Full Text] [Related]
10. SKF 38393 alters the rate-dependent D2-mediated inhibition of nigrostriatal but not mesoaccumbens dopamine neurons.
Kelland MD; Freeman AS; Chiodo LA
Synapse; 1988; 2(4):416-23. PubMed ID: 2973142
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies.
Wachtel SR; White FJ
J Pharmacol Exp Ther; 1988 Jan; 244(1):410-6. PubMed ID: 2891845
[TBL] [Abstract][Full Text] [Related]
12. Nigrostriatal lesion and dopamine agonists affect firing patterns of rodent entopeduncular nucleus neurons.
Ruskin DN; Bergstrom DA; Walters JR
J Neurophysiol; 2002 Jul; 88(1):487-96. PubMed ID: 12091570
[TBL] [Abstract][Full Text] [Related]
13. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons.
Kelland MD; Freeman AS; Chiodo LA
J Pharmacol Exp Ther; 1990 May; 253(2):803-11. PubMed ID: 1971022
[TBL] [Abstract][Full Text] [Related]
14. Chloral hydrate anesthesia alters the responsiveness of identified midbrain dopamine neurons to dopamine agonist administration.
Kelland MD; Freeman AS; Chiodo LA
Synapse; 1989; 3(1):30-7. PubMed ID: 2919369
[TBL] [Abstract][Full Text] [Related]
15. Electrophysiological and pharmacological characterization of identified nigrostriatal and mesoaccumbens dopamine neurons in the rat.
Clark D; Chiodo LA
Synapse; 1988; 2(5):474-85. PubMed ID: 2903568
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
Meltzer LT; Christoffersen CL; Serpa KA; Razmpour A
Synapse; 1993 Feb; 13(2):117-22. PubMed ID: 8446920
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiological and pharmacological characteristics of nigral dopaminergic neurons in the conscious, head-restrained rat.
Fà M; Mereu G; Ghiglieri V; Meloni A; Salis P; Gessa GL
Synapse; 2003 Apr; 48(1):1-9. PubMed ID: 12557266
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the action of the stereoisomers of the psychostimulant 4-methylaminorex (4-MAX) on midbrain dopamine cells in the rat: an extracellular single unit study.
Ashby CR; Pan H; Minabe Y; Toor A; Fishkin L; Wang RY
Synapse; 1995 Aug; 20(4):351-61. PubMed ID: 7482294
[TBL] [Abstract][Full Text] [Related]
19. An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system.
Clark D; Engberg G; Pileblad E; Svensson TH; Carlsson A; Freeman AS; Bunney BS
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun; 329(4):344-54. PubMed ID: 4033804
[TBL] [Abstract][Full Text] [Related]
20. Sigma-receptors: implication for the control of neuronal activity of nigral dopamine-containing neurons.
Engberg G; Wikström H
Eur J Pharmacol; 1991 Aug; 201(2-3):199-202. PubMed ID: 1686758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
